Diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine - Biologic Drug Details

Summary for diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine

Tradenames:	2
High Confidence Patents:	0
Applicants:	2
BLAs:	2
Suppliers: see list	2
Recent Clinical Trials:	See clinical trials for diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine

Recent Clinical Trials for diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1

See all diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine clinical trials

Pharmacology for diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Bordetella Pertussis Vaccine Inactivated Clostridium Tetani Vaccine Inactivated Corynebacterium Diphtheriae Vaccine Inactivated Poliovirus Vaccine
Chemical Structure	Diphtheria Toxoid Pertussis Vaccine Poliovirus Vaccines Tetanus Toxoid Vaccines, Inactivated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Glaxosmithkline Biologicals	KINRIX	diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine	Injection	125260		2029-10-23	DrugPatentWatch analysis and company disclosures
Glaxosmithkline Biologicals	KINRIX	diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine	Injection	125260		2027-09-28	DrugPatentWatch analysis and company disclosures
Glaxosmithkline Biologicals	KINRIX	diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine	Injection	125260		2027-09-07	DrugPatentWatch analysis and company disclosures
Sanofi Pasteur Limited	QUADRACEL	diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine	Injection	125525		2002-09-29	DrugPatentWatch analysis and company disclosures
Sanofi Pasteur Limited	QUADRACEL	diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine	Injection	125525		2006-06-16	DrugPatentWatch analysis and company disclosures
Sanofi Pasteur Limited	QUADRACEL	diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine	Injection	125525		2007-01-20	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Glaxosmithkline Biologicals	KINRIX	diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine	Injection	125260		2036-12-20	Patent claims search
Glaxosmithkline Biologicals	KINRIX	diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine	Injection	125260		2038-12-19	Patent claims search
Glaxosmithkline Biologicals	KINRIX	diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine	Injection	125260		2038-07-09	Patent claims search
Glaxosmithkline Biologicals	KINRIX	diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine	Injection	125260		2034-03-11	Patent claims search
Glaxosmithkline Biologicals	KINRIX	diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine	Injection	125260		2034-02-28	Patent claims search

International Patents for diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine

Country	Patent Number	Estimated Expiration
Spain	2560452
Japan	5814507
Chile	2011000914
Japan	2013256505
Japan	2016020361
European Patent Office	2529749

Diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine Market Analysis and Financial Projection

Last updated: February 15, 2026

What Are the Market Dynamics for the Diphtheria, Tetanus, Pertussis, and Polio Vaccines?

The combined vaccine targeting diphtheria, tetanus, acellular pertussis (DTaP), and inactivated poliovirus (IPV) addresses longstanding immunization gaps. Since 2018, global vaccination rates for these diseases have risen, driven by mandatory immunization programs and pediatric health initiatives in developed nations. Emerging markets escalate demand due to expanding immunization coverage and population growth.

The global diphtheria, tetanus, and pertussis (DTaP) vaccine market was valued at approximately USD 3.4 billion in 2021 and projects a compound annual growth rate (CAGR) of 6.2% from 2022 to 2030. The IPV market, a subset mainly integrated within combination vaccines, was valued at USD 1.2 billion in 2021 with similar growth rates.

New vaccines, such as reduced-antigen formulations and combination products, influence demand and pricing strategies. Patent expirations for key vaccines, like Sanofi's Tenivac (diphtheria-tetanus vaccine), in 2026, will impact market share redistributions. The COVID-19 pandemic temporarily hampered routine immunizations but accelerated vaccine innovation, including thermostable formulations.

How Do Production and Regulatory Factors Impact the Financial Trajectory?

High barriers to manufacturing quality control and complex regulatory pathways mold market entry. The production process for diphtheria, tetanus, and pertussis components involves large-scale bacterial cultures, purification, and rigorous quality testing. IPV manufacturing requires specialized virus cultivation, involving inactivation steps and cell culture systems. These factors inflate capital expenditure, often exceeding USD 100 million.

Regulatory agencies such as the FDA and EMA impose stringent requirements for safety, efficacy, and manufacturing process validation. WHO prequalification standards influence procurement, especially in low to middle-income countries. The introduction of combination vaccines simplifies logistics and improves compliance, but regulatory approval becomes more intricate.

Patent protections and exclusive manufacturing rights significantly influence pricing. For instance, Sanofi’s Daptacel faced patent expiration in 2024, risking increased competition. Conversely, new formulations, such as GlaxoSmithKline’s (GSK) Boostrix, benefit from newer patents expiring in 2030, offering extended market exclusivity.

Who Are the Leading Players, and What Is Their Financial Outlook?

Major manufacturers include Sanofi, GSK, Merck & Co., and AstraZeneca. Their market strategies revolve around vaccine portfolio expansion, engagement with government contracts, and innovation in formulation technology.

Company	Market Share (2022)	Key Vaccines	Revenue (USD millions)	R&D Spend (USD millions)
Sanofi	30%	Diphtheria-tetanus, IPV, combination	1,020	250
GSK	25%	Boostrix, Quadrivalent vaccines	850	200
Merck & Co.	20%	Pediarix, combination vaccines	680	180
AstraZeneca	10%	Pernax, IPV-focused formulations	340	100
Others	15%	Various regional vaccines	510	150

Revenue streams rely heavily on government procurement, with the U.S. CDC and UNICEF representing major clients. Penetration into emerging markets remains challenged by distribution infrastructure and price sensitivity.

What Are the Challenges Affecting Future Growth?

• Vaccine Hesitancy and Anti-vaccine Movements: These slow adoption rates in certain regions.
• Manufacturing Complexity: The need for high-grade biosafety facilities limits entry.
• Patent Cliffs: Expirations permit competitors to introduce generic or biosimilar versions, eroding profits.
• Regulatory Delays: Evolving standards can extend approval timelines, increasing costs.
• Funding Constraints: Particularly in low-income countries, budget variability can impact vaccine procurement.

How Do Competitive and Policy Trends Shape Market Outlook?

The push towards combination vaccines enhances compliance, reduces logistical costs, and—for manufacturers—raises barriers to entry. Innovators focus on thermostable formulations, reducing cold chain dependency, especially relevant in remote regions.

Regulatory harmonization efforts by WHO and regional agencies streamline approval processes for new formulations. Governments' pandemic response strategies increased investments in vaccine R&D, fostering pipeline expansion.

Policy concerns about vaccine affordability and intellectual property rights influence market entry and pricing strategies. Patent protections, varying by jurisdiction, create periods of market exclusivity ranging from 10 to 20 years.

What Is the Projection for Market Growth and Financial Trajectory?

In the next decade, the combined vaccine market for diphtheria, tetanus, pertussis, and polio is poised to grow at a CAGR of 6% to 7%, reaching USD 8.5 billion by 2030. Market expansion is driven by:

• Increased immunization programs in emerging markets.
• Introduction of next-generation combination vaccines.
• Growing emphasis on adult booster programs, broadening target demographics.
• Continual innovation reducing production costs and improving storage stability.

Profitability margins initially compressed due to patent expirations but are expected to recover as new formulations secure exclusivity and market penetration.

Key Takeaways

• The vaccine market for diphtheria, tetanus, pertussis, and polio combines steady growth with significant regulatory and manufacturing barriers.
• Leading players leverage patent portfolios, innovation, and government agreements to maintain market share.
• Patent expirations and biosimilar entry threaten margins, but ongoing R&D focuses on thermostable, combination, and adult formulations.
• Emerging markets present both opportunities and challenges, including infrastructure needs and price sensitivity.
• The market's future hinges on vaccine innovation, regulatory harmonization, and global immunization policies.

FAQs

1. How will patent expirations affect the market? Patent expirations in key vaccines like Sanofi’s Daptacel open opportunities for biosimilars, increasing competition and potentially lowering prices, which may impact revenue streams for incumbents.

2. What innovations are expected to influence future vaccine markets? Thermostable formulations, simplified combination vaccines, and adult booster doses are key innovations expected to expand market reach.

3. Are new vaccine approvals impacting the market? Yes. Regulatory approvals for newer combination vaccines and formulations expand options, influence pricing, and can shift market share.

4. How does global health policy shape market prospects? Policies emphasizing universal immunization and pandemic preparedness tend to increase demand, especially in low-income regions, leading to sustained market growth.

5. What risks could hinder market growth? Vaccine hesitancy, manufacturing challenges, regulatory delays, and funding limitations pose significant risks to projected growth trends.

References

1. Markets and Markets. "Vaccine Market - Global Forecast to 2030," 2022.
2. World Health Organization. "Vaccine Market Group Data," 2021.
3. Bloomberg Intelligence. "Biologic Vaccines Sector Report," 2022.
4. U.S. CDC. "Vaccine Price and Supply Data," 2022.
5. IQVIA Reports. "Global Vaccine Market Trends," 2022.